Tenderwize
Retour à la recherche

Contrat non exclusif de remise pour médicaments à base d’aflibercept

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Oct 27, 2027 · 340 days left·Open·Supplies·Framework
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Aflibercept, ausgenommen 114,3 mg/ml (ATC-Code: S01LA05).

57/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

57 / 100

Complexité

55 / 100

Facteurs de risque

The estimated value, expected quantities, guaranteed demand and detailed rebate conditions are missing.

Open-house contracts may be automatically terminated if exclusive rebate contracts enter into force during the period.

No procurement documents available

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Niedersachsen. Die Gesundheitskasse.
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Oct 27, 2027

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Conclusion of non-exclusive pharmaceutical rebate contracts under Section 130a(8) SGB V for aflibercept medicines, excluding 114.3 mg/ml and identified by ATC code S01LA05.
  • Open-house model with identical contractual conditions and access procedures for all participants; the buyer states that it will not make a selection decision or generally conduct individual negotiations.
Afficher le résumé complet

AOK Niedersachsen intends to conclude a non-exclusive open-house pharmaceutical rebate agreement for aflibercept, excluding 114.3 mg/ml, ATC code S01LA05, for performance in Germany from 1 January 2026 to 31 December 2027. Any eligible pharmaceutical entrepreneur or consortium may join on identical terms without a selection decision. The opportunity is accessible in principle, but contract documents, detailed commercial conditions, required submission documents and contract value were not provided. The structured data indicates EU funding, while the XML notice states no EU funds; this inconsistency should be clarified.

Risques

The estimated value, expected quantities, guaranteed demand and detailed rebate conditions are missing.

Open-house contracts may be automatically terminated if exclusive rebate contracts enter into force during the period.

No procurement documents available

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The participant must be a pharmaceutical entrepreneur within the meaning of Section 4(18) AMG, or a consortium of pharmaceutical entrepreneurs, in relation to the medicines...
  • The pharmaceutical entrepreneur must have its registered seat in Germany, another EU Member State, or another EEA contracting state for medicines placed on the market within...
  • A local representative may participate only if it is itself a pharmaceutical entrepreneur for the medicines offered.

Critères d'attribution

Lot 1

Price is identified as the award criterion, but no description or weighting is provided.

Acheteur

Localisation

Hannover, DEU

Identifiant

AOK- Niedersachsen. Die Gesundheitskasse

Activité

Health

Lots (1)

LOT-0000

Aflibercept Non-Exclusive Rebate Agreement

Non-exclusive open-house rebate agreement under Section 130a(8) SGB V for medicines containing aflibercept, excluding 114.3 mg/ml, ATC code S01LA05. The agreement may be concluded with all eligible pharmaceutical entrepreneurs or pharmaceutical entrepreneur consortia on uniform, non-negotiable terms. Contracts may start on the first day of a month, end no later than 31 December 2027, and may be terminated with six weeks' notice to month-end. The lot information is derived from the structured notice and TED XML notice; the underlying contract documents were not provided.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE929, Germany

Durée

Dec 2025 - Dec 2027

Catégorie

Pharmaceutical products

Critères d'attribution

Price

Date limite

Deadline Oct 27, 2027

Détails de la procédure

Date de publication
20 Nov 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
775350-2025

Appels d'offres similaires

Cookies & Privacy

With your consent, we use Google Analytics, Microsoft Clarity (session recordings) and Google Ads cookies to understand how Tenderwize is used and to measure our advertising. You can change your choice at any time via “Cookie Settings” in the footer. Cookie Policy · Privacy Policy